Ghobrial Lab

Exciting work from our lab out last week in @NatureComms: Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia @Yoshi_konnykid @IrenemGhobrial @getz_lab @DanaFarberNews

🎥 At #IMS2024, Elizabeth Lightbody of @DanaFarber discussed SWIFT-Seq, a novel method utilizing single-cell RNA sequencing of CTCs in patients with MGUS, smoldering #Myeloma, & newly diagnosed #MultipleMyeloma. Watch here: 👉 ow.ly/FMKP50UgEPn 👈 #MMSM #CaGenome #HemOnc

Nayda and Francesco presenting our immune profiling data in smoldering and released myeloma with teclistamab therapy. #ash24 #mmsm

WGS pre and post immunotherapy showing clonal selection post cart #ash24 #mmsm

Kudos to @IrenemGhobrial @LabGhobrial for the amazing work presented at #ASH24 Always pushing technology to the next level and bringing new insight in myeloma #mmsm My favorite: the use of imaging mass cytometry to understand CRS, hematotoxicity and survival after CAR T therapy

Great work by Yoshi and David on spatial proteomics on bone marrow pre and post CART #ash24 #mmsm

Thrilled to present our award achieving abstract on longitudinal single-cell immune profiling of patients with HRSMM and RRMM receiving Teclistamab at #ASH24. Thankful to my mentor @IrenemGhobrial and everyone at Ghobrial lab for the support. @DanaFarber @ASH_hematology #mmsm

This Startup Raised $5.2 Million To Develop Blood Tests For Cancer #mmsm. We are excited to launch Predicta Bio for myeloma patients forbes.com/sites/jacobwen…

@FNIH_Org Excited to be working with @FNIH_Org! @IrenemGhobrial @DanaFarberNews

Today, the FNIH Biomarkers Consortium announces the launch of a significant project to develop and validate blood-based biomarkers for predicting progression to multiple myeloma. This collaborative initiative brings together critical resources and stakeholders from the public sector, the private sector, and academia. By creating less invasive and more accurate prediction methods, we aim to enable earlier treatment and improve patient outcomes. Watch to hear more about the project from investigators Irene Ghobrial, MD, Professor of Medicine, @DanaFarber, and Bruno Paiva, PhD, Co-director, Flow Cytometry Platform & Monoclonal Gammopathies Research Laboratory, @unav Learn more at fnih.org/MMyeRisk #FNIH #BridgesToBreakthroughs #Biomarkers #BiomarkersConstortium #MultipleMyeloma #CancerResearch

Agenda - IBC. Amazing group of scientists are meeting next week to discuss early detection and interception of blood cancers. Join us virtually if you can #ibc24 #mmsm ⁦@DanaFarber⁩ ibcworkshop.org/agenda/

In contrast to our previous study of #CHIP in #multiplemyeloma which was in a different era, we now report good outcomes even in those with #myeloma and #CHIP in the era of novel agents. Yet, there is an accelerated increase in the incidence of CHIP while on #mmsm treatment.

Get to Know… Irene Ghobrial, MD bloodcancerstoday.com//post/get-to-k…

#ASH23🩸Such a great experience to finally share my IRF4 inhibitor story! Great meeting new colleagues, old friends…and you can’t beat the 🌞 in San Diego 🙌🏾! @IrenemGhobrial @JunQiLab @SiranoDhePagano

@lizlightbody presenting our data on circulating tumor cells in MGUS and SMM #ash23 #mmsm

Stay tuned for more on this exciting work from @LabGhobrial !

Great to gather with team colleagues and friends at DFCI party in San Diego!

We are excited to launch our new Centers for Early Detection and Interception. Designed for individuals with an increased risk of developing cancer, we will focus on detecting cancers sooner and stop them from developing. dana-farber.org/newsroom/news-…

Only with @IrenemGhobrial would I ever for a moment consider it possible to pull together an entire scientific conference in 3 weeks 🤯 Inaugural Center for Early Detection and Interception of Blood Cancers Scientific Retreat was a success! Already planning next year 😊

Physician-scientist @IreneGhobrial speaks about how her multidisciplinary team works hard and fast to address health disparities in bone-marrow cancer @DanaFarber. Interview by @francesgatta go.nature.com/3pIaMAJ